10-Q: Avidity Biosciences Reports Increased Loss Amid Clinical Progress

Avidity Biosciences, Inc. reported a significant increase in net loss for the first half of 2025, driven by higher R&D and G&A expenses, while advancing three key RNA therapeutic programs into late-stage clinical trials.

Summary

• Net loss for the six months ended June 30, 2025, significantly increased to $273.1 million, compared to $139.6 million for the same period in 2024.
• Research and development (R&D) expenses surged to $237.6 million for the first half of 2025, up from $130.8 million in the prior year, primarily due to increased clinical trial progression, preclinical studies, and manufacturing costs.
• General and administrative (G&A) expenses also rose to $70.5 million for the six months ended June 30, 2025, from $34.6 million in 2024, driven by higher personnel costs and professional fees.
• Cash, cash equivalents, and marketable securities totaled $1.2 billion as of June 30, 2025, which is believed to be sufficient to fund operations for at least 12 months from the filing date.
• Delpacibart zotadirsen (del-zota) for DMD44 received FDA Breakthrough Therapy designation and is on track for a Biologics License Application (BLA) submission by year-end 2025, following positive Phase 1/2 data.
• Delpacibart etedesiran (del-desiran) for DM1 completed enrollment in its global Phase 3 HARBOR trial, with topline data anticipated in Q2 2026 and marketing applications expected to begin in H2 2026.
• Delpacibart braxlosiran (del-brax) for FSHD received FDA alignment on accelerated and full approval pathways, initiated its global confirmatory Phase 3 FORTITUDE-3 study, and plans a BLA submission for accelerated approval in H2 2026.
• The company expanded its pipeline into precision cardiology with two new wholly-owned development candidates, AOC 1072 and AOC 1086.
• Avidity entered into a commercial manufacturing agreement with a Contract Manufacturing Organization (CMO) for approximately $620.0 million in minimum purchase obligations from 2026 through 2028, net of prior reservation fees.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a significant increase in net loss and cash burn, reflecting high R&D costs, this is largely expected for a biopharmaceutical company with multiple programs advancing into late-stage clinical trials. The strong clinical progress, including Breakthrough Therapy designation, completed trial enrollments, positive data readouts, and FDA alignment on approval pathways for three key programs, represents substantial operational success and future potential. The recent capital raise also provides near-term liquidity. The financial results are worse than the prior year, but the operational advancements are very strong, balancing the overall outlook.

Positives

• Delpacibart zotadirsen (del-zota) for DMD44 received FDA Breakthrough Therapy designation in July 2025, indicating potential for expedited development and review.
• Positive top-line data from the Phase 1/2 EXPLORE44 trial for del-zota demonstrated consistent, statistically significant improvements across key biomarkers and favorable safety.
• Enrollment for the Phase 2 EXPLORE44 Open-Label Extension (EXPLORE44-OLE) study for del-zota was completed in February 2025.
• Delpacibart etedesiran (del-desiran) for DM1 completed enrollment in its global Phase 3 HARBOR trial in July 2025, a significant step towards potential approval.
• Data from the MARINA-OLE trial for del-desiran showed reversal of disease progression across multiple endpoints, including hand function, myotonia, muscle strength, and activities of daily living.
• Delpacibart braxlosiran (del-brax) for FSHD achieved FDA alignment on accelerated and full approval pathways in June 2025.
• The global confirmatory Phase 3 FORTITUDE-3 study for del-brax was initiated in June 2025, alongside positive topline Phase 1/2 FORTITUDE data showing functional mobility, muscle strength, and quality of life improvements.
• The company is expanding its pipeline beyond rare neuromuscular disorders into precision cardiology with new candidates AOC 1072 and AOC 1086.
• Existing cash, cash equivalents, and marketable securities of $1.2 billion are projected to fund operations for at least 12 months, providing near-term liquidity.
• Proceeds of $185.5 million from common stock sales through the 2024 Sales Agreement were received from July 1, 2025, through August 7, 2025, bolstering cash reserves.

Negatives

• Net loss for the six months ended June 30, 2025, nearly doubled to $273.1 million from $139.6 million in the prior year.
• Research and development expenses increased significantly by $106.8 million for the six months ended June 30, 2025, reflecting higher costs associated with clinical trial progression and manufacturing.
• General and administrative expenses increased by $35.8 million for the six months ended June 30, 2025, due to higher personnel costs and professional fees.
• Cash used in operating activities increased substantially to $324.5 million for the six months ended June 30, 2025, compared to $135.4 million in the same period of 2024, indicating a higher cash burn rate.
• Accumulated deficit reached $1.2 billion as of June 30, 2025, reflecting cumulative operating losses since inception.

Risks

• The company has incurred significant operating losses since inception and expects to continue incurring net losses into the foreseeable future as it develops product candidates.
• Future cash needs will require additional financing through equity offerings, debt financings, or collaborations, and there is no assurance that such funding will be available on favorable terms or at all.
• Failure to secure adequate additional funding could force reductions in spending, extended payment terms, asset liquidation, or delays/reductions in planned development programs.
• The process of conducting preclinical studies and clinical trials is costly, time-consuming, and uncertain, with no guarantee of achieving marketing approval for any product candidates.
• Development costs may vary significantly based on factors such as trial scope, patient enrollment, manufacturing costs, and regulatory requirements.
• The company does not expect to generate revenue from product sales until successful completion of development and regulatory approval, which may not occur in the immediate term or ever.
• Significant commercialization expenses are anticipated if any product candidates receive regulatory approval, further increasing financial requirements.

Future Outlook

The company anticipates submitting its first Biologics License Application (BLA) for del-zota by year-end 2025 and plans to present additional topline and functional data from the EXPLORE44-OLE trial in Q4 2025. For del-desiran, topline data from the HARBOR study is expected in Q2 2026, with marketing application submissions in the U.S., EU, and Japan anticipated to commence in the second half of 2026. Del-brax is slated for a BLA submission for accelerated approval in H2 2026, with topline data from its biomarker cohort expected in Q2 2026. The company expects expenses and operating losses to increase as it continues preclinical studies, clinical trials, manufacturing, and builds commercial capabilities for potential product launches starting in 2026.

Management Comments

• We are committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of previously untreatable diseases.
• Our pipeline currently has three programs in potentially registrational trials, and we are advancing and expanding our innovative AOC pipeline to develop potential treatment options for people living with rare diseases across a wide range of therapeutic areas.
• We are currently building our capabilities to support potential launches of product candidates currently in clinical development and to potentially operate as a commercial organization, with plans for three potential successive product launches for DMD, DM1, and FSHD starting in 2026.
• Existing cash, cash equivalents, and marketable securities are believed to be sufficient to fund operations for at least 12 months, but future cash needs will be financed through equity offerings, debt financings, or other capital sources, including potential collaborations.

Industry Context

The company operates in the highly innovative and capital-intensive biopharmaceutical sector, specifically focusing on rare diseases and genetic conditions through its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform. This approach combines antibody specificity with RNA therapeutic precision, positioning the company at the forefront of targeted gene therapy. The advancement of multiple programs into late-stage clinical trials, including those for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), reflects a strategic focus on high-unmet-need indications. The receipt of FDA Breakthrough Therapy and Orphan Drug designations underscores the potential significance of its therapies within the rare disease landscape. Expansion into precision cardiology indicates a broader application of its AOC platform, aligning with a growing industry trend towards personalized medicine and genetic therapies. Collaborations with major pharmaceutical companies like Bristol Myers Squibb and Eli Lilly validate the platform's potential and provide non-dilutive funding and shared development costs, a common strategy for biotech companies managing high R&D expenses.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are detailed within this filing to assess against global benchmarks. However, the company's focus on Antibody Oligonucleotide Conjugates (AOCs) represents a novel approach in RNA therapeutics, differentiating it from traditional small molecule or biologic therapies.
• The rapid progression of three distinct programs (del-zota, del-desiran, del-brax) into late-stage and registrational trials, coupled with multiple FDA designations (Orphan, Fast Track, Breakthrough Therapy, Rare Pediatric Disease), suggests a highly productive and clinically successful development pipeline relative to many early-stage biopharmaceutical companies.
• The significant increase in R&D expenses and net loss is typical for a biopharmaceutical company with multiple programs advancing through costly clinical development phases, especially as manufacturing scales up for potential commercialization. This burn rate is consistent with the high investment required to bring novel therapies to market in the rare disease space.
• The company's ability to secure substantial upfront payments and potential milestones from collaborations with large pharmaceutical partners like Bristol Myers Squibb and Eli Lilly is a strong indicator of external validation for its platform and pipeline, aligning with industry best practices for risk-sharing and funding in drug development.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity offerings but also stand to benefit significantly from successful clinical trial outcomes and potential product approvals, which could drive substantial share price appreciation. The increased cash burn rate indicates higher risk but also higher investment in growth.
• **Patients:** Stand to gain from the potential development and commercialization of novel RNA therapeutics for severe rare diseases like DMD, DM1, and FSHD, which currently have limited treatment options. The rapid progression of clinical trials offers hope for new therapies.
• **Employees:** The company's expansion into new therapeutic areas and building of commercial infrastructure suggests growth opportunities and job stability, though the high burn rate implies a need for continued financial performance and capital raises.
• **Suppliers/CMOs:** Benefit from increased manufacturing and development activities, as evidenced by the significant commercial manufacturing agreement, securing future business.

Next Steps

• Submit the first Biologics License Application (BLA) for del-zota by year-end 2025.
• Present topline and functional data from the ongoing EXPLORE44-OLE trial for del-zota in the fourth quarter of 2025.
• Share updates from the ongoing MARINA-OLE trial for del-desiran, including long-term 4mg/kg efficacy and safety data, in the fourth quarter of 2025.
• Publish data analyses from the completed Phase 1/2 MARINA trial for del-desiran during 2025.
• Anticipate topline data readout from the HARBOR study for del-desiran in the second quarter of 2026.
• Begin marketing application submissions for del-desiran in the U.S., EU, and Japan in the second half of 2026.
• Share topline data from the FORTITUDE biomarker cohort for del-brax in the second quarter of 2026.
• Submit a BLA for accelerated approval for del-brax in the second half of 2026.
• Continue to execute on global commercial infrastructure development for potential product launches starting in 2026.
• Meet minimum purchase obligations under the commercial manufacturing agreement from 2026 through 2028.

Key Dates

Recommendation

The company presents a mixed financial picture with a significantly increased net loss and cash burn, which are typical for a clinical-stage biopharmaceutical company. However, the operational advancements are highly positive, with three key programs progressing to late-stage and registrational trials, securing Breakthrough Therapy designation, and achieving FDA alignment on approval pathways. The recent capital raise provides near-term liquidity. A seasoned investor would likely 'hold' to monitor the upcoming clinical data readouts and BLA submissions, as these milestones carry substantial potential for value creation, outweighing the current financial losses, provided the company continues to manage its capital effectively and execute on its development plans.

Keywords

Biopharmaceutical, RNA therapeutics, Antibody Oligonucleotide Conjugates, AOC, Duchenne muscular dystrophy, DMD, Myotonic dystrophy type 1, DM1, Facioscapulohumeral muscular dystrophy, FSHD, Clinical trials, Rare diseases, Orphan drug, Breakthrough Therapy, Biologics License Application, BLA, Drug development, Biotechnology